尚荣医疗(002551) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥484,056,837.33, a decrease of 11.94% compared to ¥549,665,108.23 in the same period last year[3] - Net profit attributable to shareholders was ¥10,452,588.72, down 79.87% from ¥51,924,560.86 year-on-year[3] - Basic earnings per share decreased by 83.33% to ¥0.01 from ¥0.06 in the same period last year[3] - Operating profit for Q1 2022 was ¥17,721,583.36, down 78% from ¥80,134,269.17 in the same period last year[28] - Total operating revenue for Q1 2022 was ¥484,056,837.33, a decrease of 12% from ¥549,665,108.23 in Q1 2021[28] - Cash flow from operating activities for Q1 2022 was ¥18,707,357.26, significantly lower than ¥77,101,655.22 in Q1 2021[29] - Research and development expenses for Q1 2022 were ¥7,389,618.53, down from ¥10,451,606.98 in Q1 2021[28] Cash Flow and Assets - The net cash flow from operating activities was ¥18,707,357.26, a decline of 75.74% compared to ¥77,101,655.22 in the previous year[3] - Cash and cash equivalents at the end of Q1 2022 totaled ¥704,018,477.93, slightly down from ¥708,633,181.73 at the end of Q1 2021[29] - Total assets at the end of the reporting period were ¥4,873,573,715.08, down 2.00% from ¥4,973,151,763.95 at the end of the previous year[3] - Accounts receivable decreased to CNY 671,341,006.79 from CNY 705,891,312.22 at the beginning of the year[24] - Inventory decreased to CNY 328,515,933.75 from CNY 375,903,468.60 at the beginning of the year[24] - The company’s long-term equity investments increased slightly to CNY 222,615,390.31 from CNY 222,183,290.16 at the beginning of the year[24] - The company’s non-current assets totaled CNY 2,574,616,971.28, showing a slight decrease from CNY 2,579,752,639.10 at the beginning of the year[24] Contracts and Projects - The company has significant ongoing contracts, including a contract with Ningling County People's Hospital valued at 150 million RMB, currently in the acceptance phase[15] - Another major contract with Chengcheng County Hospital is valued at 600 million RMB, with construction ongoing[15] - The company is currently managing multiple projects, with some in various stages of construction, including a project in Qiqihar City valued at 900 million RMB[15] - The company has a total of 14,000 RMB in a project in Inner Mongolia that is currently not started[15] - The company is actively expanding its market presence through various hospital construction projects across different provinces[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 70,341[13] - The largest shareholder, Liang Guiqiu, holds 29.55% of shares, totaling 249,586,723 shares[13] - The company has not disclosed any related party transactions among its top shareholders, except for familial relationships[13] Investment and Financing - Investment income increased by 111.98% to ¥5,028,668.98, attributed to reduced losses from joint ventures[10] - The company’s cash flow from investment activities increased by 114.53% to ¥352,523,866.88, due to reduced funds for cash management and construction projects[10] - The company approved a non-public offering of A-shares to raise up to CNY 580 million for various projects, including the industrialization of 5G digital surgical treatment systems and high-end orthopedic consumables[18] - A total of 246,055,429 shares were issued in the non-public offering, with 24,295,004 shares listed on the Shenzhen Stock Exchange on August 11, 2021[19] - The company issued 7.5 million convertible bonds in 2019, totaling 750 million RMB, with a conversion price of 4.94 RMB per share[16] - The company has a total of 75 million RMB in convertible bonds listed on the Shenzhen Stock Exchange since March 7, 2019[16] Impairment and Disputes - The company reported a 143.37% increase in credit impairment losses, amounting to ¥38,472,491.52, due to increased provisions for receivables[10] - The company is actively communicating with partners to resolve disputes related to the Qinhuangdao Guangji Hospital project, which is not expected to significantly impact current or future profits[21] Audit and Regulatory - The company did not conduct an audit for the Q1 2022 report[30] - The company has received feedback from the China Securities Regulatory Commission regarding its non-public offering and has responded accordingly[18]